Saturday 17 October 2026
Export LSDIF’s income statement to Excel — free account
Lucy Scientific Discovery Inc.
LSDIF Healthcare Drug Manufacturers Specialty & Generic
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow LSDIF
| Older periods | Mar '23 | Jun '23 | Sep '23 | Dec '23 | |
|---|---|---|---|---|---|
P/E ratio |
+5 more quarters Free account |
— | 0.00 | — | 0.00 |
P/S ratio |
— | 0.00 | — | 0.00 | |
P/FCF ratio |
— | 0.00 | — | 0.00 | |
P/Operating CF |
— | (7.85) | — | (6.32) | |
P/B ratio |
— | 3.12 | — | 57.59 | |
Price to Tangible BV |
— | 4.57 | — | 0.00 | |
EV/Sales |
— | 0.00 | — | 0.00 | |
EV/EBITDA |
— | 0.00 | — | 0.00 | |
EV/Operating CF |
— | (3.36) | — | (0.99) | |
EV/FCF |
— | (3.39) | — | (0.93) | |
Quick Ratio |
1.67 | 0.74 | 0.11 | 0.06 | |
Current Ratio |
2.80 | 1.41 | 0.71 | 0.38 | |
Net Debt/EBITDA |
1.43 | 0.69 | 0.15 | 0.24 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.50 | 0.72 | 0.64 | 0.28 | |
Capex/Depreciation |
0.00 | (10.79) | (2.61) | 0.00 | |
Interest Coverage |
(4.46) | (6.08) | (4.12) | (6.71) | |
Research and Development Expense of Revenue |
— | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 33,847.14% | 0.00% | 8,951.55% | |
Intangible Assets out of Total Assets |
0.00 | 0.17 | 0.23 | 0.34 | |
Share Based Compensation of Revenue |
0.00% | 1,507.14% | 0.00% | 185.57% | |
Graham Net Nets |
— | (0.02) | — | (0.61) | |
Graham Number |
— | 0.00 | — | 0.00 | |
Earnings Yield |
— | (61.49%) | — | (277.66%) | |
Free Cash Flow Yield |
— | (28.98%) | — | (134.99%) | |
Revenue per Share |
0.00 | 0.01 | 0.00 | 0.01 | |
Operating CF per Share |
(1.49) | (1.46) | (0.73) | (0.42) | |
Capex per Share |
0.00 | (0.24) | (0.07) | 0.00 | |
Free Cash Flow per Share |
(1.49) | (1.70) | (0.80) | (0.42) | |
Cash per Share |
2.51 | 1.32 | 0.14 | 0.12 | |
Shareholders Equity per Share |
4.37 | 3.68 | 1.54 | 0.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.37 | 3.68 | 1.54 | 0.05 | |
Free Cash Flow |
(2.03) | (2.16) | (1.41) | (0.74) | |
Working Capital |
3.73 | 1.11 | (0.64) | (2.15) | |
Capital Expenditures |
0.00 | (0.30) | (0.12) | 0.00 | |
Net Current Asset Value |
2.36 | (0.28) | (1.98) | (2.87) | |
EV/EBIT |
— | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | 42.86 | 0.00 | 0.00 | |
Price to Operating Income |
— | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 0.01 | 0.02 | |
Average Payables |
— | — | — | 2.29 | |
Average Assets |
4.70 | 4.39 | 3.13 | 4.53 | |
Average Common Equity |
— | — | (1.52) | (3.35) |
Columns are period end dates